The developed CS-based nanocarrier demonstrates significant potential in the management of peri-implantitis through its effective drug delivery mechanism. Further clinical evaluation is warranted to ascertain its efficacy in in vivo applications.
Esmailzadeh et al. (Sun,) studied this question.